Definitive Contract HHSN261201500066C
Award Date 9/22/15
Potential Completion Date 7/21/16
Potential Value $220K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35205, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
13
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Vivo Biosciences, Inc. for $279,406.00. The contract is for "SUPPORT- ADMINISTRATIVE: OTHER" services and has a completion date of July 5, 2014. As an SBIR Phase I award, this contract is intended to support the preliminary development of innovative technologies relevant to the NCI's research and program objectives. The contract was awarded on a small business...
- This is a federal contract award to Vivo Biosciences, Inc., a small business, by the National Cancer Institute (NCI) with a ceiling value of $1,882,456.20. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and an ultimate completion date of October 16, 2017. The contract was awarded on September 22, 2015 and has a "Total Small Business" set-aside designation. Based on the description, this contract is likely related to the NCI's biomedical research and...
- This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health National Cancer Institute (HHS-NIH) is valued at $392,519 to Vivosense Inc. for SBIR Topic 412: Vivosense Cancer Health Informatics Platform, Phase I. The contract is a firm fixed price award set aside for total small business under the SBIR solicitation seeking proposals for Phase I and Phase II contracts to conduct research and development supporting NIH and CDC agency missions. This...
- The National Cancer Institute awarded a $294,719 Firm Fixed Price Definitive Contract to Kiyatec Inc., a small business, for the development of a 3D human tumor co-culture system to accurately predict clinical efficacy. This Small Business Innovation Research (SBIR) Phase I contract was awarded on September 20, 2013, with a completion date of July 21, 2014. The contract was awarded under Topic 314 and aims to create a novel in vitro testing platform to improve the prediction of actual clinical...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lineage Cell Therapeutics, Inc. for the development of high content screening of 3D cultured cancer cells. The contract has a ceiling value of $285,423 and is a definitive, firm fixed-price contract with a completion date of September 4, 2014. The contract is set aside for small businesses. No other subcontractors are mentioned in the provided information.
- <p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Veloxai LLC, a small disadvantaged business. The contract is for the development of automatic treatment planning software for cervical cancer high-dose rate brachytherapy in low-resource settings, pursuant to SBIR Topic 431. The contract has a ceiling value of $2,000,000.00 and is a definitive, firm-fixed-price contract with a final completion date...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...